Document_and_Entity_Informatio
Document and Entity Information | 6 Months Ended | |
Mar. 31, 2015 | 14-May-15 | |
Document Type | 10-Q | |
Amendment Flag | FALSE | |
Document Period End Date | 31-Mar-15 | |
Trading Symbol | avxl | |
Entity Registrant Name | ANAVEX LIFE SCIENCES CORP. | |
Entity Central Index Key | 1314052 | |
Current Fiscal Year End Date | -21 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 77,243,580 | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Well Known Seasoned Issuer | No | |
Document Fiscal Year Focus | 2015 | |
Document Fiscal Period Focus | Q2 |
INTERIM_CONDENSED_CONSOLIDATED
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) | Mar. 31, 2015 | Sep. 30, 2014 |
Current | ||
Cash | $6,310,643 | $7,262,138 |
Prepaid expenses | 51,985 | 89,117 |
Total Current Assets | 6,362,628 | 7,351,255 |
Equipment | 1,749 | 2,247 |
Total Assets | 6,364,377 | 7,353,502 |
Current | ||
Accounts payable and accrued liabilities | 1,437,939 | 1,249,084 |
Promissory notes payable | 90,412 | 192,065 |
Total Current Liabilities | 1,528,351 | 1,441,149 |
Non-interest bearing liabilities | 133,727 | 5,719,727 |
Total Liabilities | 1,662,078 | 7,160,876 |
STOCKHOLDERS' EQUITY | ||
Capital stock Authorized: 400,000,000 common shares, par value $0.001 per share Issued and outstanding: 64,874,149 common shares (September 30, 2014 - 47,200,237) | 64,876 | 47,201 |
Additional paid-in capital | 59,082,325 | 52,078,750 |
Common stock to be issued | 640,000 | 640,000 |
Accumulated deficit | -55,084,902 | -52,573,325 |
Total Stockholder's Equity | 4,702,299 | 192,626 |
Total Liabilities and Stockholder's Equity | $6,364,377 | $7,353,502 |
INTERIM_CONDENSED_CONSOLIDATED1
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) | Mar. 31, 2015 | Sep. 30, 2014 |
Common Stock, Shares Authorized | 400,000,000 | 400,000,000 |
Common Stock, Par Value Per Share | $0.00 | $0.00 |
Common Stock, Shares, Issued | 64,874,149 | 47,200,237 |
Common Stock, Shares, Outstanding | 64,874,149 | 47,200,237 |
INTERIM_CONDENSED_CONSOLIDATED2
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2015 | Mar. 31, 2014 | Mar. 31, 2015 | Mar. 31, 2014 | |
Operating expenses | ||||
General and administrative | $451,193 | $903,015 | $903,246 | $1,207,443 |
Research and development | 407,146 | 118,152 | 725,771 | 123,332 |
Total operating expenses | -858,339 | -1,021,167 | -1,629,017 | -1,330,775 |
Other income (expenses) | ||||
Interest and finance income (expenses), net | 2,228 | -5,079 | -74,781 | -8,366 |
Financing related charges and adjustments | -912,357 | -1,011 | -874,706 | 681,989 |
Foreign exchange gain (loss) | 43,609 | 8,397 | 66,927 | -3,071 |
Total other income (expenses), net | -866,520 | 2,307 | -882,560 | 670,552 |
Net loss and comprehensive loss for the period | ($1,724,859) | ($1,018,860) | ($2,511,577) | ($660,223) |
Loss per share | ||||
Basic | ($0.03) | ($0.03) | ($0.05) | ($0.02) |
Diluted | ($0.03) | ($0.03) | ($0.05) | ($0.04) |
Weighted average number of shares outstanding | ||||
Basic | 57,307,779 | 37,881,209 | 54,437,890 | 37,680,823 |
Diluted | 57,307,779 | 37,881,209 | 54,437,890 | 37,680,823 |
INTERIM_CONDENSED_CONSOLIDATED3
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) | 6 Months Ended | |
Mar. 31, 2015 | Mar. 31, 2014 | |
Cash Flows used in Operating Activities | ||
Net loss for the period | ($2,511,577) | ($660,223) |
Adjustments to reconcile net loss to net cash used in operations: | ||
Amortization and depreciation | 498 | 384 |
Accretion of debt discount | 493,451 | 1,011 |
Stock-based compensation | 31,544 | 0 |
Common shares to be issued for services | 0 | 610,000 |
Amortization of deferred financing charge | 0 | 1,199 |
Non-cash financing related charges | 29,000 | -683,000 |
Change in fair value of derivative financial instruments | 487,000 | 0 |
Gain on extinguishment of debt | -105,745 | 0 |
Unrealized foreign exchange | -13,509 | -17,143 |
Changes in non-cash working capital balances related to operations: | ||
Prepaid expenses | 0 | -12,253 |
Accounts payable and accrued liabilities | 225,987 | -22,494 |
Net cash used in operating activities | -1,363,351 | -782,519 |
Cash Flows used in Investing Activities | ||
Acquisition of equipment | 0 | -2,327 |
Net cash used in investing activities | 0 | -2,327 |
Cash Flows provided by Financing Activities | ||
Issuance of common shares | 500,000 | 398,170 |
Share subscriptions received | 0 | -30,000 |
Financing fees paid | 0 | -734,840 |
Repayment of promissory note | -88,144 | 0 |
Proceeds from the issuance of convertible debentures | 0 | 10,000,000 |
Net cash provided by financing activities | 411,856 | 9,633,330 |
Decrease (increase) in cash during the period | -951,495 | 8,848,484 |
Cash, beginning of period | 7,262,138 | 345,074 |
Cash, end of period | $6,310,643 | $9,193,558 |
INTERIM_CONDENSED_CONSOLIDATED4
INTERIM CONDENSED CONSOLIDATED STATEMENT OFCHANGES INSTOCKHOLDERS' EQUITY (USD $) | Common Stock [Member] | Common Stock Additional Paid-In Capital [Member] | Common Shares to be Issued [Member] | Accumulated Deficit [Member] | Total |
Beginning Balance at Sep. 30, 2014 | $47,201 | $52,078,750 | $640,000 | ($52,573,325) | $192,626 |
Beginning Balance (Shares) at Sep. 30, 2014 | 47,200,237 | ||||
Capital stock issued pursuant to debt conversions at $0.25 | 15,676 | 3,041,031 | 3,056,707 | ||
Capital stock issued pursuant to debt conversions at $0.25 (Shares) | 15,673,912 | ||||
Capital stock issued for cash - at $0.25 | 2,000 | 2,000 | |||
Capital stock issued for cash - at $0.25 (Shares) | 2,000,000 | ||||
Reclassification of derivative liability | 3,931,000 | 3,931,000 | |||
Stock based compensation | 31,544 | 31,544 | |||
Net loss for the period | -2,511,577 | -2,511,577 | |||
Ending Balance at Mar. 31, 2015 | $64,876 | $59,082,325 | $640,000 | ($55,084,902) | $4,702,299 |
Ending Balance (Shares) at Mar. 31, 2015 | 64,874,149 |
Business_Description_and_Basis
Business Description and Basis of Presentation | 6 Months Ended | |
Mar. 31, 2015 | ||
Business Description and Basis of Presentation [Text Block] | Note 1 | Business Description and Basis of Presentation |
Business | ||
Anavex Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, and various types of cancer. The Company’s lead compounds ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), are being developed to treat Alzheimer’s disease and potentially other central nervous system (CNS) diseases. | ||
In December 2014 a Phase 2a clinical trial was initiated for ANAVEX 2-73, which is being evaluated for the treatment of Alzheimer’s disease. The randomized trial is designed to assess the safety and exploratory efficacy of ANAVEX 2-73 alone as well as in combination with donepezil (ANAVEX PLUS) in patients with mild to moderate Alzheimer’s disease. ANAVEX 2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain and to reverse the pathological hallmarks observed in Alzheimer’s disease. ANAVEX 2-73 showed no serious adverse events in a previously performed Phase 1 study. In pre-clinical studies, ANAVEX 2-73 demonstrated anti-amnesic and neuroprotective properties in various animal models including the transgenic mouse model Tg2576. | ||
The Company intends to identify and initiate discussions with potential partners in the next 12 months. Further, the Company may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further its goals. | ||
Basis of Presentation | ||
These interim condensed consolidated financial statements have been prepared, without audit pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in the annual financial statements in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information presented not misleading. | ||
These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. These interim condensed financial statements should be read in conjunction with the audited financial statements included in its annual report on Form 10-K for the year ended September 30, 2014. The Company follows the same accounting policies in the preparation of interim reports. | ||
Operating results for the six months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending September 30, 2015. | ||
Basic and Diluted Loss per Share | ||
The basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the weighted average of all potentially dilutive shares of common stock that were outstanding during the period. Additionally, the numerator is also adjusted for changes in fair value of the derivative financial instruments where it is presumed they will be share settled. | ||
As of March 31, 2015, loss per share excludes 97,345,896 (2014 – 77,305,632) potentially dilutive common shares related to outstanding options, warrants, and convertible debentures as their effect was anti-dilutive. |
Recent_Accounting_Pronouncemen
Recent Accounting Pronouncements | 6 Months Ended | |
Mar. 31, 2015 | ||
Recent Accounting Pronouncements [Text Block] | Note 2 | Recent Accounting Pronouncements |
Recent Accounting Pronouncements Not Yet Adopted | ||
In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period ("ASU 2014-12"). ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows. | ||
In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows. | ||
In May, 2014, the FASB and the International Accounting Standards Board (IASB) issued a converged standard on revenue recognition from contracts with customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard will supersede nearly all existing revenue recognition guidance. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows. | ||
Other than noted above, the Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow. |
Equipment
Equipment | 6 Months Ended | ||||||||||
Mar. 31, 2015 | |||||||||||
Equipment [Text Block] | Note 3 | Equipment | |||||||||
31-Mar-15 | |||||||||||
Accumulated | |||||||||||
Cost | Depreciation | Net | |||||||||
Computer equipment | $ | 3,015 | $ | 1,266 | $ | 1,749 | |||||
30-Sep-14 | |||||||||||
Accumulated | |||||||||||
Cost | Depreciation | Net | |||||||||
Computer equipment | $ | 3,015 | $ | 768 | $ | 2,247 |
Promissory_Notes_Payable
Promissory Notes Payable | 6 Months Ended | |||||||
Mar. 31, 2015 | ||||||||
Promissory Notes Payable [Text Block] | Note 4 | Promissory Notes Payable | ||||||
March 31, | September 30, | |||||||
2015 | 2014 | |||||||
Promissory note dated December 31, 2012 with a principal balance of CDN$100,000 bearing interest at 12% per annum, due on September 30, 2014 | $ | - | $ | 89,618 | ||||
Promissory note dated January 9, 2013 with a principal balance of CDN$86,677, bearing interest at 12% per annum, secured by all the present and future assets of the Company; due on demand | 68,553 | 77,679 | ||||||
Promissory note dated January 9, 2013 with a principal balance of CDN$27,639, bearing interest at 12% annum, secured by all the present and future assets of the Company; due on demand | 21,859 | 24,768 | ||||||
$ | 90,412 | $ | 192,065 | |||||
On December 31, 2012, the Company issued a promissory note having a principal balance of CDN$100,000, with terms that included interest at 12% per annum and matured on June 30, 2013, in exchange for an accounts payable owing with respect to unpaid consulting fees. This note was not repaid on June 30, 2013 and the maturity date was extended to September 30, 2014. The Company repaid this note during the six months ended March 31, 2015. | ||||||||
On January 9, 2013, the Company issued two (2) promissory notes (the “Secured Notes”); | ||||||||
a) | The Company issued a promissory note in the amount of CDN$86,677 to the former President, Secretary, Treasurer, CFO and director of the Company (the “President”) in exchange for unpaid consulting fees owing to the President. The note is bearing interest at 12% per annum and was due June 30, 2013. | |||||||
b) | The Company issued a promissory note in the amount of CDN$27,639 to a former director of the Company (the “Director”) in exchange for unpaid consulting fees owing to the Director. The note is bearing interest at 12% per annum and was due June 30, 2013. | |||||||
The Secured Notes are secured by a right to delay the transfer of any or all of the Company’s assets until the obligations of the Secured Notes are satisfied, including a restriction on the transfer of cash by the Company and a security interest over the intellectual property of the Company. The security interests of the Secured Notes is ranked senior to any and all security interests granted prior to the issuance of the notes and to all subsequent security interests granted, unless the holders agree in writing to other terms. | ||||||||
In addition, the Secured Notes contain a provision whereby if they are not repaid within 10 days of their maturity dates, they shall bear late fees in addition to interest accruing, at a rate of $100 per day per note. In an event of default by the Company, under the terms of the Secured Notes, the notes shall bear additional late fees of $500 per day per note. | ||||||||
Subsequent to the issuance of these Secured Notes, the former President resigned as President, Secretary, Treasurer, CFO and director of the Company and the former Director resigned as director of the Company. | ||||||||
The Company did not repay the notes on June 30, 2013. The Company has disputed the issuance and enforceability of the Secured Notes and should there be an attempt to enforce the Secured Notes or collection on them, the Company will consider a legal remedy. The Company has not accrued any late fees in connection with these Secured Notes as of March 31, 2015 or September 30, 2014, as the Company does not consider these amounts to be legally enforceable. |
Noninterest_Bearing_Liabilitie
Non-interest Bearing Liabilities | 6 Months Ended | |||||||||
Mar. 31, 2015 | ||||||||||
Non-interest Bearing Liabilities [Text Block] | Note 5 | Non-interest Bearing Liabilities | ||||||||
Non-interest bearing liabilities consists of the following: | ||||||||||
March 31, | September 30, | |||||||||
2015 | 2014 | |||||||||
Senior Convertible Debentures | $ | 133,727 | $ | 263,727 | ||||||
Derivative Financial Instruments | - | 5,456,000 | ||||||||
$ | 133,727 | $ | 5,719,727 | |||||||
Senior Convertible Debentures | ||||||||||
March 31, | September 30, | |||||||||
2015 | 2014 | |||||||||
Senior Convertible Debentures, non-interest bearing ,unsecured, due March 18, 2044 | 3,527,566 | 7,446,044 | ||||||||
Less: Debt Discount | (3,393,839 | ) | (7,182,317 | ) | ||||||
Total carrying value | 133,727 | 263,727 | ||||||||
Less: current portion | - | - | ||||||||
Long term liability | $ | 133,727 | $ | 263,727 | ||||||
On March 13, 2014, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain purchasers (the “Purchasers”) pursuant to which the Company issued senior convertible debentures in the aggregate principal amount of $10,000,000 (the “Debentures”). | ||||||||||
In connection with the issuance of the Debentures, the Company issued an aggregate of 67,666,666 share purchase warrants as follows: | ||||||||||
Non- | ||||||||||
Purchasers | purchasers | Total | ||||||||
Series A Warrants | 33,333,333 | 500,000 | 33,833,333 | |||||||
Series B Warrants | 33,333,333 | 500,000 | 33,833,333 | |||||||
66,666,666 | 1,000,000 | 67,666,666 | ||||||||
Each Series A warrant is exercisable into one common share of the Company at $0.30 per share until March 18, 2019. | ||||||||||
Each Series B warrant is exercisable into one common share of the Company at $0.42 per share until March 18, 2019 | ||||||||||
The Debentures are unsecured, non-interest bearing and are due on March 18, 2044. The Debentures were originally convertible, in whole or in part, at the option of the holder into common shares of the Company at $0.30 per share (“the Conversion Price”). The Conversion Price of the debenture will be adjusted in the event of common stock dividend, split or consolidation. The Conversion Price was later amended to $0.25 per share, as set forth below. | ||||||||||
Pursuant to the guidance of ASC 470-20 Debt with Conversion and Other Options, the Company allocated the proceeds from the issuance of the Debentures between the Debentures and the detachable Purchaser warrants using the relative fair value method. The fair value of the Purchaser warrants of $22,326,200 at issuance resulted in a debt discount at issuance of $5,989,900. | ||||||||||
The Company recorded a beneficial conversion feature discount of $4,010,100 in respect of the Debentures issued, based on the intrinsic value of the conversion feature limited to a maximum of the total proceeds of the Debentures allocated to the Debentures. | ||||||||||
The total debt discount at issuance of $10,000,000 was being amortized using the effective interest method over the term of the Debentures. | ||||||||||
In consideration for the Debentures issued, the Company issued an aggregate of 1,000,000 share purchase warrants to non-lenders as described above. The fair value of the Non- Purchaser Warrants of $334,900, along with finder’s fees and other financing costs directly associated with the issuance of the Debentures in the amount of $788,712, was recorded as a deferred financing charge and was being amortized to income over the term of the Debentures using the effective interest method. | ||||||||||
The fair value of the Purchaser and Non-Purchaser warrants at issuance was determined using the Black Scholes option pricing model with the following weighted average assumptions: | ||||||||||
Risk-free interest rate | 1.56% | |||||||||
Expected life (years) | 5 | |||||||||
Expected volatility | 97.16% | |||||||||
Dividend yields | 0.00% | |||||||||
In connection with the Purchase Agreement, the Company also entered into a registration rights agreement with each Purchaser (the “RRA”) whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) covering the resale of the shares of the Company’s common stock issuable upon conversion of the Debentures and upon exercise of the Purchaser warrants. | ||||||||||
On July 23, 2014, the registration statement was declared effective by the SEC. | ||||||||||
Amendment Agreements | ||||||||||
On August 25, 2014, the Company entered into amendment agreements with each Purchaser, pursuant to which all provisions regarding liquidating damages and the accrual of damages with respect to the obligations for, and rights enforceable against, the Company, were eliminated from the RRAs. As consideration for entering into the amendment agreements and for the Purchasers agreeing to forego an amount of $459,912 in liquidating damages that had accrued and were accruing pursuant to the terms of the original RRAs, the Company agreed to adjust the fixed conversion price of the remaining outstanding debentures from $0.30 per share to $0.25 per share (the “Debenture Amendment”). | ||||||||||
The Company assessed the guidance under ASC 470-60 Troubled Debt Restructurings and determined that this guidance did not apply to the Debenture Amendment. The Debenture Amendment was considered a substantial change in the terms of the debentures pursuant to ASC 470-50 Modifications and Extinguishments and accordingly, the Company was required to apply debt extinguishment accounting. Consequently, the Company calculated a net non-cash loss on extinguishment of debt of $8,099,137 as the premium of the aggregate fair value of the amended debentures over their aggregate carrying values of $906 immediately prior to the Debenture Amendment and the gain from the forgiveness of accrued liquidating damages of $459,912. This amount is included in other financing related charges and adjustments on the consolidated statement of operations during the year ended September 30, 2014. | ||||||||||
The Company calculated the fair value of the amended Debentures by discounting future cash flows using rates representative of current borrowing rates for debt instruments without a conversion feature and by using the binomial option pricing model to determine the fair value of the conversion features, using the following assumptions: | ||||||||||
Risk-free interest rate | 3.13% | |||||||||
Expected life (years) | 29.58 | |||||||||
Expected volatility | 100.71% | |||||||||
Dividend yields | 0.00% | |||||||||
In addition, in accordance with debt extinguishment accounting, remaining unamortized financing costs of $1,110,568 associated with the original Debentures were immediately amortized through earnings upon entering into the amendments. This amount is also included in other financing related charges and adjustments in the consolidated statement of operations during the year ended September 30, 2014. | ||||||||||
During the six months ended March 31, 2015, the Company issued an aggregate of 15,673,912 shares of common stock that were based on a conversion price of $0.25 per share pursuant to the conversion of $3,918,478 in outstanding principal amounts due under the Debentures. | ||||||||||
As a result of the bifurcation of the embedded conversion option subsequent to the Debenture Amendments as discussed above, for accounting purposes, two instruments were considered outstanding and, upon exercise of the contractual conversion option, extinguishment accounting was applied. Consequently, the embedded conversion feature was adjusted to fair value at the conversion date and the shares issued pursuant to conversion were recorded at their fair value on the date of issuance, determined with reference to the quoted market price of the Company’s shares on the issuance date. The resulting difference was recorded as a gain or loss on the consolidated statement of operations. During the six months ended March 31, 2015, the Company recorded $105,745 (2014: $Nil) in respect of net gains on these conversion of the Debentures. | ||||||||||
Effective March 26, 2015 and upon a change in triggering events, the embedded conversion option is no longer required to be bifurcated and conversion accounting has been applied to all conversions subsequent to the change in triggering events. | ||||||||||
Embedded conversion options and warrants | ||||||||||
At September 30, 2014, the Company had outstanding embedded conversion options associated with the Senior Convertible Debentures and outstanding warrants being accounted for as derivative liabilities. | ||||||||||
These derivative financial instruments arise as a result of applying ASC 815 Derivatives and Hedging (“ASC 815”), which requires the Company to make a determination whether an equity-linked financial instrument, or embedded feature, is indexed to the entity’s own stock. This guidance applies to any freestanding financial instrument or embedded features that have the characteristics of a derivative, and to any freestanding financial instruments that are potentially settled in an entity’s own stock. | ||||||||||
During the year ended September 30, 2014, the Company issued debentures with fixed price embedded conversion features and, subsequent to certain amendments as discussed above, the Company did not, at the date of issuance of these instruments, have a sufficient number of authorized and available shares of common stock to fully settle the conversion feature of such instruments if exercised. As such, the Company was required to account for these instruments as derivative financial instruments. On the amendment date of the related convertible debentures, the Company recorded a debt discount to the extent of the fair value of the embedded conversion features required to be accounted for as liabilities under ASC 815. | ||||||||||
During the six months ended March 31, 2015, the Company issued units consisting of shares of common stock and share purchase warrants and since the Company did not, at the date of issuance of these instruments, have a sufficient number of authorized and available shares of common stock to fully settle the exercise of these warrants if exercised, due to the outstanding embedded conversion features discussed above, the Company was required to account for these instruments as derivative financial instruments. On the commitment date of the related warrants, the Company allocated the proceeds from the issuance of units first to the derivative liability at its fair value, with any remaining proceeds allocated to the common stock. | ||||||||||
On March 26, 2015, the Company received stockholder approval to approve an amendment to the Company’s articles of incorporation to increase the Company’s authorized common stock from 150,000,000 to 400,000,000 shares, which is now sufficient to fully settle all the outstanding equity contracts. Consequently, these instruments previously accounted for as liabilities under ASC 815 are no longer required to be accounted for as liabilities. Pursuant to the guidance of ASC 815, the Company reclassified the fair value of these instruments on the date of this triggering event into equity, with the change in fair value up to the date of modification being recorded on the consolidated statement of operations as other income. | ||||||||||
During the year ended September 30, 2013, the Company issued an aggregate of 6,448,966 common stock purchase warrants that were required to be accounted for as liabilities pursuant to ASC 815 as a result of certain features embedded in those instruments. During the three months ended December 31, 2013, the Company amended the terms of these common stock purchase warrants. As of the modification date, these warrants were no longer required to be accounted for as liabilities. Pursuant to the guidance of ASC 815, the Company reclassified the fair value of these instruments on the date of modification into equity, with the change in fair value up to the date of modification being recorded on the consolidated statements of operations as other income. | ||||||||||
As a result of the application of ASC 815, the Company has recorded these liabilities at their fair values as follows: | ||||||||||
March 31, | September 30, | |||||||||
2015 | 2014 | |||||||||
Balance ,beginning of the period | $ | 5,456,000 | $ | 904,000 | ||||||
Fair value at issuance | 527,000 | 8,277,000 | ||||||||
Change in fair value during the period | 487,000 | (2,956,000 | ) | |||||||
Reclassification to equity upon change in triggering events | (3,931,000 | ) | (221,000 | ) | ||||||
Transfer to equity upon exercise | (2,539,000 | ) | (548,000 | ) | ||||||
Balance, end of the period | $ | - | $ | 5,456,000 | ||||||
The embedded conversion features and warrants accounted for as derivative financial instruments have no observable market and the Company estimated their fair values at their reclassification dates and September 30, 2014 using the binomial option pricing model based on the following weighted average management assumptions: | ||||||||||
Reclassification | September | |||||||||
Date | 30, 2014 | |||||||||
Risk-free interest rate | 1.47% | 3.21% | ||||||||
Expected life (years) | 24.19 | 29.48 | ||||||||
Expected volatility | 102.14% | 100.07% | ||||||||
Dividend yields | 0.00% | 0.00% |
Capital_Stock
Capital Stock | 6 Months Ended | |
Mar. 31, 2015 | ||
Capital Stock [Text Block] | Note 6 | Capital Stock |
Authorized | ||
On March 26, 2015, the Company received stockholder approval to approve an amendment to the Company’s articles of incorporation to increase the Company’s authorized common stock from 150,000,000 to 400,000,000 shares. | ||
Equity Transactions | ||
On October 22, 2014, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with one investor for an equity investment of $500,000 at a price of $0.25 per unit. Pursuant to the terms of the Purchase Agreement, the Company agreed to sell, and Lincoln Park agreed to purchase, 2,000,000 shares of common stock. In addition, the Company agreed to issue an aggregate of 4,000,000 stock purchase warrants, of which 2,000,000 are exercisable at $0.30 per share and 2,000,000 are exercisable at $0.42 per share, each for a period of five years, subject to normal adjustment for stock splits, combinations, and reclassification events. | ||
As discussed in Note 5, the warrants issued were required to be accounted for as derivative liabilities at their date of issuance, pursuant to the guidance of ASC 815. Consequently, the Company allocated the proceeds from the issuance of the units first to the warrants, at their fair value of $527,000 with an amount of $2,000 being allocated to equity at par value. The $29,000 excess of the sum of fair value and par value over the proceeds received of $500,000 was recorded as a component of financing related charges and adjustments on the statement of operations during the six months ended March 31, 2015. The fair value of the warrants was determined based on the binomial option pricing model using the following weighted average assumptions: risk-free interest rate: 1.46%, expected life: 5 years, expected volatility: 100.21%, dividend yield: 0%. | ||
The Company paid a finder’s fee of $50,000 in connection with the purchase agreement. This amount was expensed as a component of financing related charges and adjustments during the six months ended March 31, 2015. | ||
Common stock to be issued | ||
On February 28, 2014, the Company received $30,000 in share subscriptions in respect of the issuance of 100,000 units at $0.30 per unit. Each unit consisted of one common share and one common share purchase warrant entitling the holder to purchase additional common shares at $0.75 per share for a period of five years from the date of issuance. | ||
Included in common stock to be issued at March 31, 2015 is an amount of $610,000 (September 30, 2014: $610,000) related to 1,000,000 of common stock issuable to a director and officer of the Company pursuant to the terms of an employment agreement with that director and officer (Note 8). |
Lincoln_Park_Purchase_Agreemen
Lincoln Park Purchase Agreement | 6 Months Ended | |
Mar. 31, 2015 | ||
Lincoln Park Purchase Agreement [Text Block] | Note 7 | Lincoln Park Purchase Agreement |
On July 5, 2013, the Company entered into a $10,000,000 purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC, (“Lincoln Park”) an Illinois limited liability company (the “Financing”) pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $10,000,000 in value of its shares of common stock from time to time over a 25 month period. In connection with the Financing, the Company also entered into a registration rights agreement with Lincoln Park whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) covering the shares of the Company’s common stock that may be issued to Lincoln Park under the Purchase Agreement. | ||
The Company will determine, at its own discretion, the timing and amount of its sales of common stock, subject to certain conditions and limitations. The purchase price of the shares that may be sold to Lincoln Park under the Purchase Agreement will be based on the market price of the Company’s shares of common stock immediately preceding the time of sale without any fixed discount, provided that in no event will such shares be sold to Lincoln Park when the closing sale price is less than $0.50 per share. There are no upper limits on the per share price that Lincoln Park may pay to purchase such common stock. The purchase price will be equitably adjusted for any reorganization, recapitalization, non- cash dividend, stock split or similar transaction occurring during the business days used to compute such price. | ||
Pursuant to the Purchase Agreement, Lincoln Park initially purchased 250,000 shares of the Company’s common stock for $100,000. In consideration for entering into the Purchase Agreement, the Company issued to Lincoln Park 341,858 shares of common stock as a commitment fee and shall issue up to 133,409 shares pro rata, when and if, Lincoln Park purchases, at the Company’s discretion, the remaining $10,000,000 aggregate commitment. The Purchase Agreement may be terminated by the Company at any time at its discretion without any cost to the Company. | ||
On October 23, 2013, the registration statement was declared effective by the SEC. | ||
The Company incurred a net $73,787 in direct expenses in connection with the Purchase Agreement and registration statement. These were recorded as share issuance costs as a charge against additional paid in capital in the period incurred. | ||
During the six months ended March 31, 2015, the Company did not issue any shares under the Purchase Agreement. |
Related_Party_Transactions
Related Party Transactions | 6 Months Ended | ||
Mar. 31, 2015 | |||
Related Party Transactions [Text Block] | Note 8 | Related Party Transactions | |
During the three and six months ended March 31, 2015, the Company was charged general and administrative expenses totaling $16,082 and $32,465, respectively (2014: $Nil and $Nil, respectively) in respect of directors fees and stock option based compensation charges paid or accrued to directors and officers of the Company, inclusive of amounts noted below. | |||
As at March 31, 2015, included in accounts payable and accrued liabilities was $40,016 (September 30, 2014: $28,232) owing to directors and officers of the Company for director fees and reimbursable expenses, and a former director and officer of the Company for unpaid fees. | |||
During the year ended September 30, 2013, pursuant to an employment agreement with the President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer, and Director, of the Company, the Company: | |||
i) | granted 2,000,000 fully vested share purchase options exercisable at $0.40 per share until July 5, 2023. | ||
ii) | issued 4,000,000 shares of restricted common stock that vest as follows: | ||
• | 25% upon the Company starting a Phase Ib/IIb human study | ||
• | 25% upon the Company in-licensing additional assets in clinical or pre-clinical stage (vested during the year ended September 30, 2014 at a value of $610,000) | ||
• | 25% upon the Company securing additional non-dilutive equity funding in 2013 of at least $5,000,000 with a share price higher than the previous funding | ||
• | 25% upon the Company obtaining a listing on a major stock exchange |
Commitments
Commitments | 6 Months Ended | |||||||||||||||||
Mar. 31, 2015 | ||||||||||||||||||
Commitments [Text Block] | Note 9 | Commitments | ||||||||||||||||
a) | Share Purchase Warrants | |||||||||||||||||
A summary of the Company’s share purchase warrants outstanding is presented below: | ||||||||||||||||||
Weighted | ||||||||||||||||||
Average | ||||||||||||||||||
Exercise | ||||||||||||||||||
Number of Shares | Price | |||||||||||||||||
Balance, October 1, 2013 | 9,149,479 | $ | 0.75 | |||||||||||||||
Expired | (2,700,513 | ) | $ | 0.75 | ||||||||||||||
Issued | 68,466,666 | $ | 0.36 | |||||||||||||||
Balance, September 30, 2014 | 74,915,632 | $ | 0.4 | |||||||||||||||
Expired | (250,000 | ) | $ | 0.19 | ||||||||||||||
Issued | 4,300,000 | $ | 0.35 | |||||||||||||||
Balance, March 31, 2015 | 78,965,632 | $ | 0.4 | |||||||||||||||
At March 31, 2015, the Company has 78,965,632 currently exercisable share purchase warrants outstanding as follows: | ||||||||||||||||||
Number | Exercise Price | Expiry Date | ||||||||||||||||
6,448,966 | $ | 0.75 | 5-Jul-18 | |||||||||||||||
500,000 | $ | 0.75 | 14-Feb-19 | |||||||||||||||
120,000 | $ | 1 | 24-Feb-19 | |||||||||||||||
33,833,333 | $ | 0.3 | 13-Mar-19 | |||||||||||||||
33,833,333 | $ | 0.42 | 13-Mar-19 | |||||||||||||||
180,000 | $ | 0.31 | 31-May-19 | |||||||||||||||
2,000,000 | $ | 0.3 | 22-Oct-19 | |||||||||||||||
2,000,000 | $ | 0.42 | 22-Oct-19 | |||||||||||||||
50,000 | $ | 0.31 | 31-May-19 | |||||||||||||||
78,965,632 | ||||||||||||||||||
During the six months ended March 31, 2015, the Company issued 250,000 warrants exercisable at $0.19 per share until January 31, 2015 to a consultant of the Company pursuant to a consulting agreement dated October 24, 2014. The warrants were to vest in the event the Company entered into a license agreement or direct sales transaction as a direct result of the consultant. During the six months ended March 31, 2015, these warrants expired unvested and unexercised. No stock-based compensation has been or will be recorded in the financial statements as none of the performance conditions for vesting were met. | ||||||||||||||||||
During the six months ended March 31, 2015, the Company issued 50,000 warrants exercisable at $0.31 per share until May 31, 2019 to a consultant of the Company pursuant to a consulting agreement. The fair value of these warrants at issuance was calculated to be $6,000 based on the Black-Scholes option pricing model using the following assumptions: expected term 4.59 years, expected volatility 102.33%, expected dividend yield 0.00%, risk free interest rate 1.58%. Stock based compensation will be recorded in the financial statements over the vesting term of three years from the date of grant. | ||||||||||||||||||
All of the 6,448,966 warrants expiring on July 5, 2018 and the 500,000 warrants expiring February 14, 2019 contain a contingent call provision whereby the Company may have the option to call for cancellation of all or any portion of the warrants for consideration equal to $0.001 per share, provided the quoted market price of the Company’s common stock exceeds $1.50 for a period of twenty consecutive trading days, subject to certain minimum volume restrictions and other restrictions as provided in the warrant agreements. | ||||||||||||||||||
b) | Stock–based Compensation Plan | |||||||||||||||||
In April, 2007, the Company adopted a stock option plan which provides for the granting of stock options to selected directors, officers, employees or consultants in an aggregate amount of up to 3,000,000 common shares of the Company and, in any case, the number of shares to be issued to any one individual pursuant to the exercise of options shall not exceed 10% of the issued and outstanding share capital. The granting of stock options, exercise prices and terms are determined by the Company's Board of Directors. If no vesting schedule is specified by the Board of Directors on the grant of options, then the options shall vest over a 4 -year period with 25% of the granted options vesting each year commencing 1 year from the grant date. For stockholders who have greater than 10% of the outstanding common shares of the Company and who have granted options, the exercise price of their options shall not be less than 110% of the fair of the stock on grant date. Otherwise, options granted shall have an exercise price equal to their fair value on grant date. | ||||||||||||||||||
On February 2, 2011, the Company amended and restated the 2007 stock option plan to increase the number of options authorized to 4,000,000. | ||||||||||||||||||
A summary of the status of Company’s outstanding stock purchase options for the six months ended March 31, 2015 and for the year ended September 30, 2014 is presented below: | ||||||||||||||||||
Weighted | Weighted | |||||||||||||||||
Number of | Average | Average Grant | ||||||||||||||||
Shares | Exercise Price | Date fair value | ||||||||||||||||
Outstanding at October 1, 2013 | 3,075,000 | $ | 1.26 | |||||||||||||||
Expired | (705,000 | ) | $ | 2.7 | ||||||||||||||
Granted | 800,000 | $ | 0.32 | $ | 0.25 | |||||||||||||
Outstanding at September 30, 2014 and March 31, 2015 | 3,170,000 | $ | 0.7 | |||||||||||||||
Exercisable at March 31, 2015 | 2,100,000 | $ | 0.56 | |||||||||||||||
Exercisable at September 30, 2014 | 2,100,000 | $ | 0.56 | |||||||||||||||
At March 31, 2015, the following stock options were outstanding: | ||||||||||||||||||
Number of Shares | Aggregate | Remaining | ||||||||||||||||
Number | Exercise | Intrinsic | Contractual | |||||||||||||||
Total | Vested | Price | Expiry Date | Value | Life (yrs) | |||||||||||||
100,000 | -1 | 100,000 | $ | 3.67 | 30-Mar-16 | - | 1 | |||||||||||
270,000 | -2 | - | $ | 3 | 8-Feb-17 | - | 1.86 | |||||||||||
2,000,000 | -3 | 2,000,000 | $ | 0.4 | 5-Jul-23 | - | 8.27 | |||||||||||
300,000 | -4 | - | $ | 0.3 | 7-May-24 | - | 9.11 | |||||||||||
500,000 | -5 | - | $ | 0.33 | 8-May-24 | - | 9.11 | |||||||||||
3,170,000 | 2,100,000 | - | ||||||||||||||||
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market price of the Company’s stock for the options that were in-the-money at March 31, 2015. | ||||||||||||||||||
-1 | As of March 31, 2015 and September 30, 2014, these options had fully vested. These options were granted during the year ended September 30, 2011 and vested over a period of one year from the date of grant. The fair value of these options at issuance was calculated to be $267,000. The Company did not recognize any stock- based compensation during the three and six months ended March 31, 2015 (2014: $Nil and $Nil, respectively) in connection with these options. | |||||||||||||||||
-2 | As of March 31, 2015 and September 30, 2014, none of these options had vested. The options vest upon one or more compounds: entering Phase II trial – 90,000 options; entering Phase III trial – 90,000 options; and receiving FDA approval – 90,000 options. No stock-based compensation has been recorded in the financial statements as none of the performance conditions have yet been met. | |||||||||||||||||
-3 | As of March 31, 2015 and September 30, 2014 these options had fully vested. These options were granted during the year ended September 30, 2013 and vested immediately upon granting. The Company did not recognize any stock-based compensation during the three and six months ended March 31, 2015 (2014: $Nil and $Nil, respectively) in connection with these options. | |||||||||||||||||
-4 | As of March 31, 2015 and September 30, 2014, none of these options had vested. These options were issued during the year ended September 30, 2014 and vest annually over a three year period commencing on the first anniversary of the date of the grant. The Company recognized stock based compensation expense of $5,830 and $11,660 during the three and six months ended March 31, 2015, respectively (2014: $Nil and $Nil, respectively) in connection with these options. These amounts have been included in general and administrative expenses on the Company’s statement of operations. | |||||||||||||||||
-5 | As of March 31, 2015 and September 30, 2014, none of these options had vested. These options were issued during the year ended September 30, 2014 and vest annually over a four year period commencing on the first anniversary of the date of the grant. The Company recognized stock based compensation expense of $8,053 and $16,106 during the three and six months ended March 31, 2015, respectively (2014: $Nil and $Nil, respectively) in connection with these options. | |||||||||||||||||
During the six months ended March 31, 2014, 505,000 options expired for which the Company had recognized stock-based compensation of $Nil and $Nil during the three and six months ended March 31, 2014, respectively. | ||||||||||||||||||
There has been no stock-based compensation recognized in the financial statements for the three and six months ended March 31, 2015 (2014: $nil) for options that will vest upon the achievement of performance milestones because the Company has determined that satisfaction of the performance milestones was not probable. Compensation relating to stock options exercisable upon achieving performance milestones will be recognized in the period the milestones are achieved. |
Subsequent_Events
Subsequent Events | 6 Months Ended | ||
Mar. 31, 2015 | |||
Subsequent Events [Text Block] | Note 10 | Subsequent Events | |
Subsequent to March 31, 2015; | |||
i) | the Company granted stock options to purchase an aggregate of 2,875,000 shares of common stock of the Company at an exercise price of $0.23 per share for a period of 10 years from the date of issuance. The options shall vest in three equal annual instalments. | ||
ii) | the Company issued 4,378,954 shares of common stock of the Company pursuant to the exercise of share purchase warrants at $0.30 per share. |
Supplemental_Cash_Flow_Informa
Supplemental Cash Flow Information | 6 Months Ended | ||
Mar. 31, 2015 | |||
Supplemental Cash Flow Information [Text Block] | Note 11 | Supplemental Cash Flow Information | |
Investing and financing activities that do not have a direct impact on current cash flows are excluded from the statement of cash flows. | |||
During the six months ended March 31, 2015; | |||
i) | the Company issued 15,673,912 shares of common stock upon conversion of convertible debentures at a conversion price of $0.25 per share; | ||
ii) | the Company reclassified an amount of $3,931,000 into equity upon modification of the terms of certain derivative instruments. | ||
During the six months ended March 31, 2014, the Company reclassified an amount of $221,000 into equity upon modification of the terms of certain derivative instruments. | |||
These transactions have been excluded from the statement of cash flows. |
Equipment_Tables
Equipment (Tables) | 6 Months Ended | 12 Months Ended | ||||||||||||||||||||
Mar. 31, 2015 | Sep. 30, 2014 | |||||||||||||||||||||
Schedule of Property, Plant and Equipment [Table Text Block] | 31-Mar-15 | 30-Sep-14 | ||||||||||||||||||||
Accumulated | Accumulated | |||||||||||||||||||||
Cost | Depreciation | Net | Cost | Depreciation | Net | |||||||||||||||||
Computer equipment | $ | 3,015 | $ | 1,266 | $ | 1,749 | Computer equipment | $ | 3,015 | $ | 768 | $ | 2,247 |
Promissory_Notes_Payable_Table
Promissory Notes Payable (Tables) | 6 Months Ended | |||||||
Mar. 31, 2015 | ||||||||
Schedule of Debt [Table Text Block] | March 31, | September 30, | ||||||
2015 | 2014 | |||||||
Promissory note dated December 31, 2012 with a principal balance of CDN$100,000 bearing interest at 12% per annum, due on September 30, 2014 | $ | - | $ | 89,618 | ||||
Promissory note dated January 9, 2013 with a principal balance of CDN$86,677, bearing interest at 12% per annum, secured by all the present and future assets of the Company; due on demand | 68,553 | 77,679 | ||||||
Promissory note dated January 9, 2013 with a principal balance of CDN$27,639, bearing interest at 12% annum, secured by all the present and future assets of the Company; due on demand | 21,859 | 24,768 | ||||||
$ | 90,412 | $ | 192,065 |
Noninterest_Bearing_Liabilitie1
Non-interest Bearing Liabilities (Tables) | 6 Months Ended | |||||||||
Mar. 31, 2015 | ||||||||||
Non-interest bearing liabilities [Table Text Block] | March 31, | September 30, | ||||||||
2015 | 2014 | |||||||||
Senior Convertible Debentures | $ | 133,727 | $ | 263,727 | ||||||
Derivative Financial Instruments | - | 5,456,000 | ||||||||
$ | 133,727 | $ | 5,719,727 | |||||||
Schedule Of Convertible Debt [Table Text Block] | March 31, | September 30, | ||||||||
2015 | 2014 | |||||||||
Senior Convertible Debentures, non-interest bearing ,unsecured, due March 18, 2044 | 3,527,566 | 7,446,044 | ||||||||
Less: Debt Discount | (3,393,839 | ) | (7,182,317 | ) | ||||||
Total carrying value | 133,727 | 263,727 | ||||||||
Less: current portion | - | - | ||||||||
Long term liability | $ | 133,727 | $ | 263,727 | ||||||
Company Issuance of Share Purchase Warrants [Table Text Block] | Non- | |||||||||
Purchasers | purchasers | Total | ||||||||
Series A Warrants | 33,333,333 | 500,000 | 33,833,333 | |||||||
Series B Warrants | 33,333,333 | 500,000 | 33,833,333 | |||||||
66,666,666 | 1,000,000 | 67,666,666 | ||||||||
Fair Value of the Purchaser and Non-Purchaser Warrants at Issuance [Table Text Block] | Risk-free interest rate | 1.56% | ||||||||
Expected life (years) | 5 | |||||||||
Expected volatility | 97.16% | |||||||||
Dividend yields | 0.00% | |||||||||
Schedule of Fair Value of Liabilities Activity [Table Text Block] | March 31, | September 30, | ||||||||
2015 | 2014 | |||||||||
Balance ,beginning of the period | $ | 5,456,000 | $ | 904,000 | ||||||
Fair value at issuance | 527,000 | 8,277,000 | ||||||||
Change in fair value during the period | 487,000 | (2,956,000 | ) | |||||||
Reclassification to equity upon change in triggering events | (3,931,000 | ) | (221,000 | ) | ||||||
Transfer to equity upon exercise | (2,539,000 | ) | (548,000 | ) | ||||||
Balance, end of the period | $ | - | $ | 5,456,000 | ||||||
Amendment Agreements [Member] | ||||||||||
Fair Value of the Purchaser and Non-Purchaser Warrants at Issuance [Table Text Block] | Risk-free interest rate | 3.13% | ||||||||
Expected life (years) | 29.58 | |||||||||
Expected volatility | 100.71% | |||||||||
Dividend yields | 0.00% | |||||||||
Embedded conversion options and warrants [Member] | ||||||||||
Fair Value of the Purchaser and Non-Purchaser Warrants at Issuance [Table Text Block] | Reclassification | September | ||||||||
Date | 30, 2014 | |||||||||
Risk-free interest rate | 1.47% | 3.21% | ||||||||
Expected life (years) | 24.19 | 29.48 | ||||||||
Expected volatility | 102.14% | 100.07% | ||||||||
Dividend yields | 0.00% | 0.00% |
Commitments_Tables
Commitments (Tables) | 6 Months Ended | |||||||||||||||||
Mar. 31, 2015 | ||||||||||||||||||
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block] | Weighted | |||||||||||||||||
Average | ||||||||||||||||||
Exercise | ||||||||||||||||||
Number of Shares | Price | |||||||||||||||||
Balance, October 1, 2013 | 9,149,479 | $ | 0.75 | |||||||||||||||
Expired | (2,700,513 | ) | $ | 0.75 | ||||||||||||||
Issued | 68,466,666 | $ | 0.36 | |||||||||||||||
Balance, September 30, 2014 | 74,915,632 | $ | 0.4 | |||||||||||||||
Expired | (250,000 | ) | $ | 0.19 | ||||||||||||||
Issued | 4,300,000 | $ | 0.35 | |||||||||||||||
Balance, March 31, 2015 | 78,965,632 | $ | 0.4 | |||||||||||||||
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Number | Exercise Price | Expiry Date | |||||||||||||||
6,448,966 | $ | 0.75 | 5-Jul-18 | |||||||||||||||
500,000 | $ | 0.75 | 14-Feb-19 | |||||||||||||||
120,000 | $ | 1 | 24-Feb-19 | |||||||||||||||
33,833,333 | $ | 0.3 | 13-Mar-19 | |||||||||||||||
33,833,333 | $ | 0.42 | 13-Mar-19 | |||||||||||||||
180,000 | $ | 0.31 | 31-May-19 | |||||||||||||||
2,000,000 | $ | 0.3 | 22-Oct-19 | |||||||||||||||
2,000,000 | $ | 0.42 | 22-Oct-19 | |||||||||||||||
50,000 | $ | 0.31 | 31-May-19 | |||||||||||||||
78,965,632 | ||||||||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | Weighted | Weighted | ||||||||||||||||
Number of | Average | Average Grant | ||||||||||||||||
Shares | Exercise Price | Date fair value | ||||||||||||||||
Outstanding at October 1, 2013 | 3,075,000 | $ | 1.26 | |||||||||||||||
Expired | (705,000 | ) | $ | 2.7 | ||||||||||||||
Granted | 800,000 | $ | 0.32 | $ | 0.25 | |||||||||||||
Outstanding at September 30, 2014 and March 31, 2015 | 3,170,000 | $ | 0.7 | |||||||||||||||
Exercisable at March 31, 2015 | 2,100,000 | $ | 0.56 | |||||||||||||||
Exercisable at September 30, 2014 | 2,100,000 | $ | 0.56 | |||||||||||||||
Schedule of Nonvested Share Activity [Table Text Block] | Number of Shares | Aggregate | Remaining | |||||||||||||||
Number | Exercise | Intrinsic | Contractual | |||||||||||||||
Total | Vested | Price | Expiry Date | Value | Life (yrs) | |||||||||||||
100,000 | -1 | 100,000 | $ | 3.67 | 30-Mar-16 | - | 1 | |||||||||||
270,000 | -2 | - | $ | 3 | 8-Feb-17 | - | 1.86 | |||||||||||
2,000,000 | -3 | 2,000,000 | $ | 0.4 | 5-Jul-23 | - | 8.27 | |||||||||||
300,000 | -4 | - | $ | 0.3 | 7-May-24 | - | 9.11 | |||||||||||
500,000 | -5 | - | $ | 0.33 | 8-May-24 | - | 9.11 | |||||||||||
3,170,000 | 2,100,000 | - |
Business_Description_and_Basis1
Business Description and Basis of Presentation (Narrative) (Details) | 6 Months Ended |
Mar. 31, 2015 | |
M | |
Business Description And Basis Of Presentation 1 | 12 |
Business Description And Basis Of Presentation 2 | 97,345,896 |
Business Description And Basis Of Presentation 3 | 77,305,632 |
Promissory_Notes_Payable_Narra
Promissory Notes Payable (Narrative) (Details) | 6 Months Ended | |
Mar. 31, 2015 | Mar. 31, 2015 | |
USD ($) | CAD | |
D | ||
Promissory Notes Payable 1 | 100,000 | |
Promissory Notes Payable 2 | 12.00% | 12.00% |
Promissory Notes Payable 3 | 86,677 | |
Promissory Notes Payable 4 | 12.00% | 12.00% |
Promissory Notes Payable 5 | 27,639 | |
Promissory Notes Payable 6 | 12.00% | 12.00% |
Promissory Notes Payable 7 | 10 | 10 |
Promissory Notes Payable 8 | 100 | |
Promissory Notes Payable 9 | $500 |
Noninterest_Bearing_Liabilitie2
Non-interest Bearing Liabilities (Narrative) (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
Non-interest Bearing Liabilities 1 | $10,000,000 |
Non-interest Bearing Liabilities 2 | 67,666,666 |
Non-interest Bearing Liabilities 3 | $0.30 |
Non-interest Bearing Liabilities 4 | $0.42 |
Non-interest Bearing Liabilities 5 | $0.30 |
Non-interest Bearing Liabilities 6 | $0.25 |
Non-interest Bearing Liabilities 7 | 22,326,200 |
Non-interest Bearing Liabilities 8 | 5,989,900 |
Non-interest Bearing Liabilities 9 | 4,010,100 |
Non-interest Bearing Liabilities 10 | 10,000,000 |
Non-interest Bearing Liabilities 11 | 1,000,000 |
Non-interest Bearing Liabilities 12 | 334,900 |
Non-interest Bearing Liabilities 13 | 788,712 |
Non-interest Bearing Liabilities 14 | 459,912 |
Non-interest Bearing Liabilities 15 | $0.30 |
Non-interest Bearing Liabilities 16 | $0.25 |
Non-interest Bearing Liabilities 17 | 8,099,137 |
Non-interest Bearing Liabilities 18 | 906 |
Non-interest Bearing Liabilities 19 | 459,912 |
Non-interest Bearing Liabilities 20 | 1,110,568 |
Non-interest Bearing Liabilities 21 | 15,673,912 |
Non-interest Bearing Liabilities 22 | $0.25 |
Non-interest Bearing Liabilities 23 | 3,918,478 |
Non-interest Bearing Liabilities 24 | 105,745 |
Non-interest Bearing Liabilities 25 | $0 |
Non-interest Bearing Liabilities 26 | 150,000,000 |
Non-interest Bearing Liabilities 27 | 400,000,000 |
Non-interest Bearing Liabilities 28 | 6,448,966 |
Capital_Stock_Narrative_Detail
Capital Stock (Narrative) (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
Y | |
Capital Stock 1 | 150,000,000 |
Capital Stock 2 | 400,000,000 |
Capital Stock 3 | $500,000 |
Capital Stock 4 | $0.25 |
Capital Stock 5 | 2,000,000 |
Capital Stock 6 | 4,000,000 |
Capital Stock 7 | 2,000,000 |
Capital Stock 8 | $0.30 |
Capital Stock 9 | 2,000,000 |
Capital Stock 10 | $0.42 |
Capital Stock 11 | 527,000 |
Capital Stock 12 | 2,000 |
Capital Stock 13 | 29,000 |
Capital Stock 14 | 500,000 |
Capital Stock 15 | 1.46% |
Capital Stock 16 | 5 |
Capital Stock 17 | 100.21% |
Capital Stock 18 | 0.00% |
Capital Stock 19 | 50,000 |
Capital Stock 20 | 30,000 |
Capital Stock 21 | 100,000 |
Capital Stock 22 | $0.30 |
Capital Stock 23 | $0.75 |
Capital Stock 24 | 610,000 |
Capital Stock 25 | $610,000 |
Capital Stock 26 | 1,000,000 |
Lincoln_Park_Purchase_Agreemen1
Lincoln Park Purchase Agreement (Narrative) (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
M | |
Lincoln Park Purchase Agreement 1 | $10,000,000 |
Lincoln Park Purchase Agreement 2 | 10,000,000 |
Lincoln Park Purchase Agreement 3 | 25 |
Lincoln Park Purchase Agreement 4 | $0.50 |
Lincoln Park Purchase Agreement 5 | 250,000 |
Lincoln Park Purchase Agreement 6 | 100,000 |
Lincoln Park Purchase Agreement 7 | 341,858 |
Lincoln Park Purchase Agreement 8 | 133,409 |
Lincoln Park Purchase Agreement 9 | 10,000,000 |
Lincoln Park Purchase Agreement 10 | $73,787 |
Related_Party_Transactions_Nar
Related Party Transactions (Narrative) (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
Related Party Transactions 1 | $16,082 |
Related Party Transactions 2 | 32,465 |
Related Party Transactions 3 | 0 |
Related Party Transactions 4 | 0 |
Related Party Transactions 5 | 40,016 |
Related Party Transactions 6 | 28,232 |
Related Party Transactions 7 | 2,000,000 |
Related Party Transactions 8 | $0.40 |
Related Party Transactions 9 | 4,000,000 |
Related Party Transactions 10 | 25.00% |
Related Party Transactions 11 | 25.00% |
Related Party Transactions 12 | 610,000 |
Related Party Transactions 13 | 25.00% |
Related Party Transactions 14 | $5,000,000 |
Related Party Transactions 15 | 25.00% |
Commitments_Narrative_Details
Commitments (Narrative) (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
Y | |
Commitments 1 | 78,965,632 |
Commitments 2 | 250,000 |
Commitments 3 | $0.19 |
Commitments 4 | 50,000 |
Commitments 5 | $0.31 |
Commitments 6 | $6,000 |
Commitments 7 | 4.59 |
Commitments 8 | 102.33% |
Commitments 9 | 0.00% |
Commitments 10 | 1.58% |
Commitments 11 | 6,448,966 |
Commitments 12 | 500,000 |
Commitments 13 | $0.00 |
Commitments 14 | 1.5 |
Commitments 15 | 3,000,000 |
Commitments 16 | 10.00% |
Commitments 17 | 4 |
Commitments 18 | 25.00% |
Commitments 19 | 1 |
Commitments 20 | 10.00% |
Commitments 21 | 110.00% |
Commitments 22 | 4,000,000 |
Commitments 23 | 267,000 |
Commitments 24 | 0 |
Commitments 25 | 0 |
Commitments 26 | 90,000 |
Commitments 27 | 90,000 |
Commitments 28 | 90,000 |
Commitments 29 | 0 |
Commitments 30 | 0 |
Commitments 31 | 5,830 |
Commitments 32 | 11,660 |
Commitments 33 | 0 |
Commitments 34 | 0 |
Commitments 35 | 8,053 |
Commitments 36 | 16,106 |
Commitments 37 | 0 |
Commitments 38 | 0 |
Commitments 39 | 505,000 |
Commitments 40 | 0 |
Commitments 41 | 0 |
Commitments 42 | $0 |
Subsequent_Events_Narrative_De
Subsequent Events (Narrative) (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
Y | |
Subsequent Events 1 | 2,875,000 |
Subsequent Events 2 | $0.23 |
Subsequent Events 3 | 10 |
Subsequent Events 4 | 4,378,954 |
Subsequent Events 5 | $0.30 |
Supplemental_Cash_Flow_Informa1
Supplemental Cash Flow Information (Narrative) (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
Supplemental Cash Flow Information 1 | 15,673,912 |
Supplemental Cash Flow Information 2 | $0.25 |
Supplemental Cash Flow Information 3 | $3,931,000 |
Supplemental Cash Flow Information 4 | $221,000 |
Schedule_of_Property_Plant_and
Schedule of Property, Plant and Equipment (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
Equipment Schedule Of Property, Plant And Equipment 1 | $3,015 |
Equipment Schedule Of Property, Plant And Equipment 2 | 1,266 |
Equipment Schedule Of Property, Plant And Equipment 3 | 1,749 |
Equipment Schedule Of Property, Plant And Equipment 1 | 3,015 |
Equipment Schedule Of Property, Plant And Equipment 2 | 768 |
Equipment Schedule Of Property, Plant And Equipment 3 | $2,247 |
Schedule_of_Debt_Details
Schedule of Debt (Details) | 6 Months Ended | |
Mar. 31, 2015 | Mar. 31, 2015 | |
USD ($) | CAD | |
Promissory Notes Payable Schedule Of Debt 1 | 100,000 | |
Promissory Notes Payable Schedule Of Debt 2 | 12.00% | 12.00% |
Promissory Notes Payable Schedule Of Debt 3 | 0 | |
Promissory Notes Payable Schedule Of Debt 4 | 89,618 | |
Promissory Notes Payable Schedule Of Debt 5 | 86,677 | |
Promissory Notes Payable Schedule Of Debt 6 | 12.00% | 12.00% |
Promissory Notes Payable Schedule Of Debt 7 | 68,553 | |
Promissory Notes Payable Schedule Of Debt 8 | 77,679 | |
Promissory Notes Payable Schedule Of Debt 9 | 27,639 | |
Promissory Notes Payable Schedule Of Debt 10 | 12.00% | 12.00% |
Promissory Notes Payable Schedule Of Debt 11 | 21,859 | |
Promissory Notes Payable Schedule Of Debt 12 | 24,768 | |
Promissory Notes Payable Schedule Of Debt 13 | 90,412 | |
Promissory Notes Payable Schedule Of Debt 14 | $192,065 |
Recovered_Sheet1
Non-interest bearing liabilities (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
Non-interest Bearing Liabilities Non-interest Bearing Liabilities 1 | $133,727 |
Non-interest Bearing Liabilities Non-interest Bearing Liabilities 2 | 263,727 |
Non-interest Bearing Liabilities Non-interest Bearing Liabilities 3 | 0 |
Non-interest Bearing Liabilities Non-interest Bearing Liabilities 4 | 5,456,000 |
Non-interest Bearing Liabilities Non-interest Bearing Liabilities 5 | 133,727 |
Non-interest Bearing Liabilities Non-interest Bearing Liabilities 6 | $5,719,727 |
Schedule_Of_Convertible_Debt_D
Schedule Of Convertible Debt (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
Non-interest Bearing Liabilities Schedule Of Convertible Debt 1 | $3,527,566 |
Non-interest Bearing Liabilities Schedule Of Convertible Debt 2 | 7,446,044 |
Non-interest Bearing Liabilities Schedule Of Convertible Debt 3 | -3,393,839 |
Non-interest Bearing Liabilities Schedule Of Convertible Debt 4 | -7,182,317 |
Non-interest Bearing Liabilities Schedule Of Convertible Debt 5 | 133,727 |
Non-interest Bearing Liabilities Schedule Of Convertible Debt 6 | 263,727 |
Non-interest Bearing Liabilities Schedule Of Convertible Debt 7 | 0 |
Non-interest Bearing Liabilities Schedule Of Convertible Debt 8 | 0 |
Non-interest Bearing Liabilities Schedule Of Convertible Debt 9 | 133,727 |
Non-interest Bearing Liabilities Schedule Of Convertible Debt 10 | $263,727 |
Company_Issuance_of_Share_Purc
Company Issuance of Share Purchase Warrants (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
Non-interest Bearing Liabilities Company Issuance Of Share Purchase Warrants 1 | $33,333,333 |
Non-interest Bearing Liabilities Company Issuance Of Share Purchase Warrants 2 | 500,000 |
Non-interest Bearing Liabilities Company Issuance Of Share Purchase Warrants 3 | 33,833,333 |
Non-interest Bearing Liabilities Company Issuance Of Share Purchase Warrants 4 | 33,333,333 |
Non-interest Bearing Liabilities Company Issuance Of Share Purchase Warrants 5 | 500,000 |
Non-interest Bearing Liabilities Company Issuance Of Share Purchase Warrants 6 | 33,833,333 |
Non-interest Bearing Liabilities Company Issuance Of Share Purchase Warrants 7 | 66,666,666 |
Non-interest Bearing Liabilities Company Issuance Of Share Purchase Warrants 8 | 1,000,000 |
Non-interest Bearing Liabilities Company Issuance Of Share Purchase Warrants 9 | $67,666,666 |
Fair_Value_of_the_Purchaser_an
Fair Value of the Purchaser and Non-Purchaser Warrants at Issuance (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 1 | 1.56% |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 2 | 5 |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 3 | 97.16% |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 4 | 0.00% |
Amendment Agreements [Member] | |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 1 | 3.13% |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 2 | 29.58 |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 3 | 100.71% |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 4 | 0.00% |
Embedded conversion options and warrants [Member] | |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 1 | 30 |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 2 | 1.47% |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 3 | 3.21% |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 4 | 24.19 |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 5 | 29.48 |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 6 | 102.14% |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 7 | 100.07% |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 8 | 0.00% |
Non-interest Bearing Liabilities Fair Value Of The Purchaser And Non-purchaser Warrants At Issuance 9 | 0.00% |
Schedule_of_Fair_Value_of_Liab
Schedule of Fair Value of Liabilities Activity (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
Non-interest Bearing Liabilities Schedule Of Fair Value Of Liabilities Activity 1 | $5,456,000 |
Non-interest Bearing Liabilities Schedule Of Fair Value Of Liabilities Activity 2 | 904,000 |
Non-interest Bearing Liabilities Schedule Of Fair Value Of Liabilities Activity 3 | 527,000 |
Non-interest Bearing Liabilities Schedule Of Fair Value Of Liabilities Activity 4 | 8,277,000 |
Non-interest Bearing Liabilities Schedule Of Fair Value Of Liabilities Activity 5 | 487,000 |
Non-interest Bearing Liabilities Schedule Of Fair Value Of Liabilities Activity 6 | -2,956,000 |
Non-interest Bearing Liabilities Schedule Of Fair Value Of Liabilities Activity 7 | -3,931,000 |
Non-interest Bearing Liabilities Schedule Of Fair Value Of Liabilities Activity 8 | -221,000 |
Non-interest Bearing Liabilities Schedule Of Fair Value Of Liabilities Activity 9 | -2,539,000 |
Non-interest Bearing Liabilities Schedule Of Fair Value Of Liabilities Activity 10 | -548,000 |
Non-interest Bearing Liabilities Schedule Of Fair Value Of Liabilities Activity 11 | 0 |
Non-interest Bearing Liabilities Schedule Of Fair Value Of Liabilities Activity 12 | $5,456,000 |
Schedule_of_Stockholders_Equit
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1 | $9,149,479 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 2 | 0.75 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 3 | -2,700,513 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 4 | 0.75 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 5 | 68,466,666 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 6 | 0.36 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 7 | 74,915,632 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 8 | 0.4 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 9 | -250,000 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 10 | 0.19 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 11 | 4,300,000 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 12 | 0.35 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 13 | $78,965,632 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 14 | 0.4 |
Schedule_of_Stockholders_Equit1
Schedule of Stockholders' Equity Note, Warrants or Rights (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 1 | $6,448,966 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 2 | 0.75 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 3 | 500,000 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 4 | 0.75 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 5 | 120,000 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 6 | 1 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 7 | 33,833,333 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 8 | 0.3 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 9 | 33,833,333 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 10 | 0.42 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 11 | 180,000 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 12 | 0.31 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 13 | 2,000,000 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 14 | 0.3 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 15 | 2,000,000 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 16 | 0.42 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 17 | 50,000 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 18 | 0.31 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 19 | $78,965,632 |
Schedule_of_Sharebased_Compens
Schedule of Share-based Compensation, Stock Options, Activity (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 1 | $3,075,000 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 2 | 1.26 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 3 | -705,000 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 4 | 2.7 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 5 | 800,000 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 6 | 0.32 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 7 | 0.25 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 8 | 3,170,000 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 9 | 0.7 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 10 | 2,100,000 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 11 | 0.56 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 12 | $2,100,000 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 13 | 0.56 |
Schedule_of_Nonvested_Share_Ac
Schedule of Nonvested Share Activity (Details) (USD $) | 6 Months Ended |
Mar. 31, 2015 | |
Commitments Schedule Of Nonvested Share Activity 1 | $100,000 |
Commitments Schedule Of Nonvested Share Activity 2 | 100,000 |
Commitments Schedule Of Nonvested Share Activity 3 | 3.67 |
Commitments Schedule Of Nonvested Share Activity 4 | 0 |
Commitments Schedule Of Nonvested Share Activity 5 | 1 |
Commitments Schedule Of Nonvested Share Activity 6 | 270,000 |
Commitments Schedule Of Nonvested Share Activity 7 | 0 |
Commitments Schedule Of Nonvested Share Activity 8 | 3 |
Commitments Schedule Of Nonvested Share Activity 9 | 0 |
Commitments Schedule Of Nonvested Share Activity 10 | 1.86 |
Commitments Schedule Of Nonvested Share Activity 11 | 2,000,000 |
Commitments Schedule Of Nonvested Share Activity 12 | 2,000,000 |
Commitments Schedule Of Nonvested Share Activity 13 | 0.4 |
Commitments Schedule Of Nonvested Share Activity 14 | 0 |
Commitments Schedule Of Nonvested Share Activity 15 | 8.27 |
Commitments Schedule Of Nonvested Share Activity 16 | 300,000 |
Commitments Schedule Of Nonvested Share Activity 17 | 0 |
Commitments Schedule Of Nonvested Share Activity 18 | 0.3 |
Commitments Schedule Of Nonvested Share Activity 19 | 0 |
Commitments Schedule Of Nonvested Share Activity 20 | 9.11 |
Commitments Schedule Of Nonvested Share Activity 21 | 500,000 |
Commitments Schedule Of Nonvested Share Activity 22 | 0 |
Commitments Schedule Of Nonvested Share Activity 23 | 0.33 |
Commitments Schedule Of Nonvested Share Activity 24 | 0 |
Commitments Schedule Of Nonvested Share Activity 25 | 9.11 |
Commitments Schedule Of Nonvested Share Activity 26 | 3,170,000 |
Commitments Schedule Of Nonvested Share Activity 27 | 2,100,000 |
Commitments Schedule Of Nonvested Share Activity 28 | $0 |